Product image of Laevolac Ameixa (Lactulose, Liquid) supplied by GNH India

Laevolac Ameixa

Active Ingredient:
Lactulose, Liquid
Origin:
EU

Laevolac Ameixa (Lactulose, Liquid)

Lactulose, the active ingredient in Laevolac Ameixa, is an osmotic laxative presented as a liquid oral solution for oral use. It is used to treat constipation and to prevent hepatic encephalopathy in patients with liver disease. It works by increasing osmotic pressure in the intestinal lumen, drawing water into the bowel to soften stools and reduce ammonia absorption.

GNH India supplies Laevolac Ameixa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for import.

Manufacturer / TM Owner

Ferraz Lynce, S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Laevolac Ameixa (lactulose) is employed in the management of conditions related to bowel motility and hepatic ammonia accumulation.

  • Constipation: softens stools and facilitates regular bowel movements.
  • Hepatic encephalopathy: lowers intestinal ammonia production to help prevent neuropsychiatric episodes.
  • Recurrent hepatic encephalopathy: maintains low ammonia levels to reduce the frequency of episodes.

How It Works

  • Lactulose is a synthetic disaccharide that is not absorbed in the small intestine. In the colon it is metabolised by bacterial enzymes into acidic compounds, which increase the osmotic pressure within the lumen, drawing water into the bowel to soften stools and also acidify colonic contents, thereby reducing ammonia absorption into the portal circulation.

Side Effects

Lactulose may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

  • Bloating: sensation of abdominal fullness.
  • Flatulence: increased intestinal gas.
  • Abdominal cramps: intermittent stomach pain.
  • Diarrhoea: loose stools, especially at higher doses.
  • Nausea: feeling of sickness.
  • Electrolyte imbalance: mild changes in sodium or potassium levels.

Serious or Rare Side Effects

  • Severe dehydration: excessive fluid loss requiring medical attention.
  • Allergic reaction: rash, itching, swelling, or difficulty breathing.
  • Hypernatremia: markedly elevated blood sodium.
  • Hepatic encephalopathy worsening: paradoxical increase in ammonia in rare cases.

Precautions & Warnings

Before using Laevolac Ameixa, consider the following safety measures.

  • Assess renal function: use with caution in severe renal impairment.
  • Monitor electrolytes: watch for hyponatremia or potassium shifts.
  • Avoid in galactosemia: product may contain lactose-derived excipients.
  • Use caution in diabetic patients: monitor blood glucose as lactulose can affect carbohydrate metabolism.
  • Pregnancy and lactation: consult a healthcare professional before use.
  • Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Lactulose can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid)

  • Broad‑spectrum antibiotics (e.g., neomycin, rifaximin): may reduce colonic bacterial conversion of lactulose, diminishing its effect.
  • Antacids containing magnesium: can increase the osmotic load and exacerbate diarrhoea.

Moderate Interactions (Monitor Closely)

  • Diuretics: concurrent use may increase the risk of electrolyte disturbances.
  • Insulin or oral hypoglycaics: lactulose may affect glucose control; monitor blood sugar levels.
  • Other laxatives: combined use can lead to excessive bowel movements and dehydration.

Frequently Asked Questions

Laevolac Ameixa contains lactulose, an osmotic laxative indicated for the relief of constipation and for the prevention or treatment of hepatic encephalopathy in patients with liver disease. It works by softening stools and reducing intestinal ammonia absorption.

Lactulose is a synthetic sugar that reaches the colon unchanged, where gut bacteria ferment it into short‑chain acids. This acidifies the colonic environment, increases osmotic pressure, draws water into the lumen to soften stools, and lowers ammonia absorption, helping to prevent hepatic encephalopathy.

The dose of Laevolac Ameixa is individualized by the prescribing clinician based on the patient’s condition, age, renal function and response. Typical regimens range from a few millilitres to larger volumes, but the exact amount must be determined by a qualified healthcare professional.

Safety data for lactulose in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by a healthcare provider after evaluating the specific situation.

To request Laevolac Ameixa, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lactulose differs from polyethylene glycol or magnesium‑based laxatives by acting as a fermentable osmotic agent that also lowers colonic ammonia. While polyethylene glycol primarily draws water into the bowel, lactulose provides the added benefit of ammonia reduction, making it the preferred choice for patients at risk of hepatic encephalopathy.

Store Laevolac Ameixa at ambient temperature, ideally below 25 °C. Keep the container tightly closed, protect it from moisture and direct sunlight, and retain it in the original packaging to maintain product stability.

Laevolac Ameixa is taken orally as a liquid solution. It can be measured with a calibrated dosing device and swallowed directly or mixed with a small amount of water or juice to improve palatability, following the prescribing clinician’s instructions.

Serious adverse events, although rare, include severe dehydration, electrolyte disturbances such as hypernatremia, and allergic reactions that may present as rash, swelling or breathing difficulty. Prompt medical attention is required if any of these symptoms develop.

Laevolac Ameixa should be avoided in patients with known hypersensitivity to lactulose, those with galactosemia, and individuals with intestinal obstruction or severe diarrhoea where further laxation could be harmful. Contra‑indications must be confirmed by a healthcare professional.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lactulose, Liquid

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT